At Styx, we are reprogramming immune cells to generate more robust and enduring immune responses. Our pioneering approach has remarkably improved the effectiveness of existing, fragile vaccines, and developing novel vaccine-based therapies against deadly diseases like COVID-19, pancreatic cancer, among others.
LifeSci
Styx Biotechnologies
OTHER COMPANIES
